Prospective Natural History Study of Smoking Immune Cell Profiles Epigenetics and COVID-19

  • STATUS
    Recruiting
  • participants needed
    200
  • sponsor
    National Institute of Environmental Health Sciences (NIEHS)
Send
Updated on 5 August 2020
See if I qualify
body mass index
covid-19
blood test
social interaction

Summary

Background

Early evidence in the COVID-19 pandemic suggests that smokers are at a higher risk of having severe effects or dying from the disease. Smoking causes changes in immune cells. Researchers think this may be the reason why smokers are more likely to have severe effects from COVID-19. Researchers want to better understand the interaction between smoking history, the immune system, and COVID-19.

Objective

To better understand how COVID-19 affects smokers and non-smokers immune systems before and after being infected with the virus.

Eligibility

Healthy people ages 30-55 who are a smokers or non-smokers who may potentially contract COVID-19

Design

Participants will be screened over the phone. They will answer questions about their demographics, medical history, medications, and smoking status.

Participants will have up to 6 monthly visits.

At the first visit, participants will have blood tests. Blood will be drawn through a needle in an arm vein. They will provide a saliva sample in a container. Their height and weight will be taken. They will complete questionnaires about their medical history and smoking status.

Participants will then have monthly visits. They will have blood draws to test for COVID-19 antibodies. These visits will occur 4 times or until they have a positive antibody result.

Participants will have a final visit. They will have blood tests.

If at any time participants test positive for a COVID-19, they will be rescheduled 14 days or more after they no longer have symptoms....

Description

Study Description: This study is a prospective, longitudinal, observational, single-center, exploratory study to collect samples and data that will enable explorations of the interaction between smoking, immune system characteristics and Coronavirus Disease 2019 (COVID-19). This study will collect baseline samples and data prior to COVID-19 infection required to explore these interactions prospectively. Early evidence in the COVID-19 pandemic suggests that smokers have higher risk for morbidity and mortality associated with COVID-19 infection. We have identified smoking-associated altered epigenetics, transcription and changes in immune cell profiles. Smoking exposure drives loss of naive CD8+ T cells and increases in senescent CD8+ T cells and these effects are signs of immune system dysfunction. We propose that the immune system senescence associated with prior smoking is a susceptibility factor in COVID-19 morbidity.

Objectives

Primary Objective: To prospectively collect biospecimens and data at baseline and longitudinally in an identified fashion from eligible participants and retain for future use to better understand the interaction between smoking history, immune cell profiles and the natural history of COVID-19 morbidity. We hypothesize that senescent CD8 T cells will be higher in smokers who develop COVID-19.

To test this hypothesis, we will establish a bank of cryopreserved peripheral blood mononuclear cells (PBMCs) from before and after COVID-19 exposure from smokers and nonsmokers and use mass cytometry (CyTOF) to analyze detailed immune profiles, test if the frequency of senescent CD8 T cells is higher among smokers who develop COVID-19 (antibody positivity) relative to those who do not develop COVID-19 positivity.

Exploratory Objective: To compare potential immunological biomarkers of susceptibility to viral infection with genetic, epigenetic and other biological characteristics measured in blood before and after recovery from COVID-19 illness and develop assays that indicate immune cell dysfunction and COVID-19 susceptibility.

Endpoints

Primary Endpoint: Levels of senescent CD16+CD8+ T cells before COVID-19 and time to COVID-19 morbidity.

Exploratory Endpoints:

  1. Smoking exposure biomarkers
  2. Immune cell profiles identified by CyTOF assays or other single cell assays
  3. Transcriptional profiles from immune cell subtypes
  4. DNA methylation profiles of candidate genes in immune cell subtypes

Study Population: Male and female participants aged 30 to 55 years old, generally healthy with a history of smoking (n=60) and nonsmoking (n=30).

Description of Sites/Facilities Enrolling Participants: All visits will be conducted at the NIEHS Clinical Research Unit (CRU) in Durham, North Carolina, USA.

Study Duration: Estimated time from enrollment to completion of data analyses is 24 months.

Participant Duration: Estimated average amount of time for a participant to complete all study visits is 6 months.

Details
Condition Covid 19
Age 30years - 55years
Clinical Study IdentifierNCT04403386
SponsorNational Institute of Environmental Health Sciences (NIEHS)
Last Modified on5 August 2020

Eligibility

 Yes No Not Sure

Inclusion Criteria

b'In order to be eligible to participate in this study, an individual must meet all of the'
b'following criteria:'
b'Stated willingness to comply with all study procedures and availability for the'
b'duration of the study'
b'Male and females'
b'Age 30 to 55 years'
b'Able to travel to study visits at the NIEHS CRU for required study visits'
b'Body mass index (BMI) range between 18 and 35 at enrollment'
b'Must self-identify as a current smoker (cigarettes and/or use of an e-cigarette/vaping'
b'device), have smoked for 5 years or longer or identify as a non-smoker, having never'
b'used of any other forms of tobacco, nicotine, or smoked marijuana and not currently'
b'residing with a smoker'

Exclusion Criteria

b'An individual who meets any of the following criteria will be excluded from participation'
b'in this study:'
b'History of confirmed COVID-19 infection'
b'Current diagnosis of cancer or prior history of cancer'
b'Bleeding disorder or any reason that a blood sample cannot be provided'
b'Current pregnancy or lactation, by participant verbal confirmation.'
b"Any condition that, in the investigator's opinion, places the participant at undue"
b'risk for complications associated with required study procedures'
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

body mass index
covid-19
blood test
social interaction

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.